Cargando…

A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer

OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTC) are often diagnosed late and at an advanced stage. Population-based screening programmes do not exist and diagnosis is primarily dependent on symptom recognition. Recently symptom-based cancer decision support tools...

Descripción completa

Detalles Bibliográficos
Autores principales: Keane, M G, Horsfall, L, Rait, G, Pereira, S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244441/
https://www.ncbi.nlm.nih.gov/pubmed/25410605
http://dx.doi.org/10.1136/bmjopen-2014-005720
_version_ 1782346228904755200
author Keane, M G
Horsfall, L
Rait, G
Pereira, S P
author_facet Keane, M G
Horsfall, L
Rait, G
Pereira, S P
author_sort Keane, M G
collection PubMed
description OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTC) are often diagnosed late and at an advanced stage. Population-based screening programmes do not exist and diagnosis is primarily dependent on symptom recognition. Recently symptom-based cancer decision support tools (CDSTs) have been introduced into primary care practices throughout the UK to support general practitioners (GPs) in identifying patients with suspected PDAC. However, future refinement of these tools to improve their diagnostic accuracy is likely to be necessary. SETTING: The Health Improvement Network (THIN) is a primary care database, which includes more than 11 million electronic patient records, from 562 GP practices in the UK. PARTICIPANTS: All patients with a diagnosis of PDAC or BTC between 2000 and 2010 were included in the study along with six matched controls; 2773 patients with PDAC, 848 patients with BTC and 15 395 controls. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary aim of this study was to determine the early symptom profiles of PDAC and BTC. Secondary aims included comparing early symptom trends between BTC and PDAC, defining symptom onset in PDAC and evaluating trends in routine blood tests nearest to the time of diagnosis. RESULTS: In the year prior to diagnosis, patients with PDAC visited their GP on a median of 18 (IQR 11–27) occasions. PDAC was associated with 11 alarm symptoms and BTC with 8. Back pain (OR 1.33 (95% CI 1.18 to 1.49) p<0.001), lethargy (1.42 (95% CI 1.25 to 1.62) p<0.001) and new onset diabetes (OR 2.46 (95% CI 2.16 to 2.80)) were identified as unique features of PDAC. CONCLUSIONS: PDAC and BTC are associated with numerous early alarm symptoms. CDSTs are therefore likely to be useful in identifying these tumours at an early stage. Inclusion of unique symptoms, symptoms with an early onset and routinely performed blood tests is likely to further improve the sensitivity of these tools.
format Online
Article
Text
id pubmed-4244441
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-42444412014-11-28 A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer Keane, M G Horsfall, L Rait, G Pereira, S P BMJ Open Gastroenterology and Hepatology OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTC) are often diagnosed late and at an advanced stage. Population-based screening programmes do not exist and diagnosis is primarily dependent on symptom recognition. Recently symptom-based cancer decision support tools (CDSTs) have been introduced into primary care practices throughout the UK to support general practitioners (GPs) in identifying patients with suspected PDAC. However, future refinement of these tools to improve their diagnostic accuracy is likely to be necessary. SETTING: The Health Improvement Network (THIN) is a primary care database, which includes more than 11 million electronic patient records, from 562 GP practices in the UK. PARTICIPANTS: All patients with a diagnosis of PDAC or BTC between 2000 and 2010 were included in the study along with six matched controls; 2773 patients with PDAC, 848 patients with BTC and 15 395 controls. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary aim of this study was to determine the early symptom profiles of PDAC and BTC. Secondary aims included comparing early symptom trends between BTC and PDAC, defining symptom onset in PDAC and evaluating trends in routine blood tests nearest to the time of diagnosis. RESULTS: In the year prior to diagnosis, patients with PDAC visited their GP on a median of 18 (IQR 11–27) occasions. PDAC was associated with 11 alarm symptoms and BTC with 8. Back pain (OR 1.33 (95% CI 1.18 to 1.49) p<0.001), lethargy (1.42 (95% CI 1.25 to 1.62) p<0.001) and new onset diabetes (OR 2.46 (95% CI 2.16 to 2.80)) were identified as unique features of PDAC. CONCLUSIONS: PDAC and BTC are associated with numerous early alarm symptoms. CDSTs are therefore likely to be useful in identifying these tumours at an early stage. Inclusion of unique symptoms, symptoms with an early onset and routinely performed blood tests is likely to further improve the sensitivity of these tools. BMJ Publishing Group 2014-11-19 /pmc/articles/PMC4244441/ /pubmed/25410605 http://dx.doi.org/10.1136/bmjopen-2014-005720 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Gastroenterology and Hepatology
Keane, M G
Horsfall, L
Rait, G
Pereira, S P
A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer
title A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer
title_full A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer
title_fullStr A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer
title_full_unstemmed A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer
title_short A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer
title_sort case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer
topic Gastroenterology and Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244441/
https://www.ncbi.nlm.nih.gov/pubmed/25410605
http://dx.doi.org/10.1136/bmjopen-2014-005720
work_keys_str_mv AT keanemg acasecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer
AT horsfalll acasecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer
AT raitg acasecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer
AT pereirasp acasecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer
AT keanemg casecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer
AT horsfalll casecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer
AT raitg casecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer
AT pereirasp casecontrolstudycomparingtheincidenceofearlysymptomsinpancreaticandbiliarytractcancer